Pseudohyperaldosteronism: Pathogenetic Mechanisms

REFERENCES

• Kater CE, Biglieri EG, Brust, et al. Stimulation and suppression of the mineralocorticoid hormones in normal subjects and adrencocorticortical disorders. Endocr Rev 1989; 10: 149–164.
   PubMed Web of Science ®Google Scholar
• Quinn SJ, Williams GH. Regulation of aldosterone secretion. Annu Rev Physiol 1988: 50: 409–426.
   PubMed Web of Science ®Google Scholar
• Williams GH, Dluhy RG. Control of aldosterone secretion. In: Genest J, Küchel O, Hamet P, eds. Hypertension: Physiopathology and Treatment. 2nd ed. Pp 320-337. New York: McGraw-Hill, 1983.
   Google Scholar
• McKenna TJ, Island DP, Nicholson WE, et al. The effects of potassium on early and late steps in aldosterone biosynthesis in cells of the zona glomerulosa. Endocrinology 1978: 103: 1411–1416.
   PubMedGoogle Scholar
• Kramer RE, Gallant S, Brownie AC. Actions of angiotensin II on aldosterone biosynthesis in the rat adrenal cortex. J Biol Chem 1980; 255: 3442–3447.
   PubMedGoogle Scholar
• Himathongkam T, Dluhy RG, Williams GH. Potassium-aldosterone-renin interrelationships. J Clin Endocrinol Metab 1975; 41: 153–159.
   PubMed Web of Science ®Google Scholar
• Knox FG, Burnett JC Jr, Kohan DE, et al. Escape from the sodium-retaining effects of mineralocorticoids. Kidney Int 1980; 65: 765–772.
   Google Scholar
• Miyamori I, Ikeda M, Matubara T, et al. Human natriuretic polypeptide during escape from mineralocorticoid excess in man. Clin Sci 1987; 73: 431–436.
   Google Scholar
• Armanini D, Witzgall H, Wehling M, et al. Aldosterone receptors in different types of primary hyperaldosteronism. J Clin Endocrinol Metab 1987; 65: 101–104.
   PubMedGoogle Scholar
• Irony I, Biglieri EG. The Sindrome of hyperdeoxycorticosteronism. In: Biglieri EG, Melby JC, eds. Endocrine Hypertension. Pp 175-181. New York: Raven Press, 1990.
   Google Scholar
• Kono T, Miyake T. The volume of distribution, metabolic clearance rate and mean plasma concentration of aldosterone, cortisol and corticosterone in various clinical conditions. Proc Second Internat Congr Endocrinol. Excerpta Med Congr Series. 1965; 83: 246–257.
   Google Scholar
• Sasano H, Fukushima K, Sasaki I, et al. Immunolocalization of mineralocorticoid receptor in human kidney, pancreas, salivary, mammary and sweat glands: a light and electron microscopic immunohistochemical study. J Endocrinol 1992; 132: 305–310.
   PubMed Web of Science ®Google Scholar
• Fukushima K, Sasano H, Nagura H. Immunohistochemical localization of mineralocorti-coid receptor in human gut. Tohoku J Exp Med 1991; 165: 155–163.
   PubMedGoogle Scholar
• Pressley L, Funder JW. Glucocorticoid and mineralocorticoid receptors in gut mucosa. Endocrinology 1975; 97: 588–596.
   PubMedGoogle Scholar
• Gesing A, Bilang BA, Droste SK, et al. Psychological stress increases hippocampal mineralocorticoid receptor levels: involment of corticotropin-releasing hormone. J Neurosci 2001; 21: 4822–4829.
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Sibug RM, De Kloet ER, et al. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension. Eur J Pharmacol 2002; 436: 207–216.
   PubMedGoogle Scholar
• Le Menuet D, Isnard R, Bichara M, et al. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 2001; 276: 38911–20.
   PubMed Web of Science ®Google Scholar
• Armanini D, Strasser T, Weber PC. Characterization of aldosterone receptors in human mononuclear leukocytes. Am J Physiol 1985; 11, E388–390.
   Google Scholar
• Suzuki T, Sasano H, Suzuki S, et al. 11beta-hydroxysteroid dehydrogenase type 2 in human lung: possible regulator of mineralocorticoid action. J Clin Endocrinol Metab 1998; 83: 4022–4025.
   PubMedGoogle Scholar
• Stokes J, Noble J, Brett L, et al. Distribution of glucocorticoid and mineralocorticoid receptors and 11beta-hydroxysteroid dehydrogenase in human and rat ocular tissues. Invest Ophthalmol Vis Sci 2000; 41:1629-1638.
   PubMedGoogle Scholar
• Mirshahi M, Mirshahi A, Sedighian R, et al. Immunochemical demonstration of the mineralocorticoid receptor in ocular tissue. Neuroendocrinology 1997; 65: 70–78.
   PubMedGoogle Scholar
• Funder JW. Mineralocorticoid receptors and glucocorticoid receptors. Clin Endocrinol (Oxford) 1996; 45: 651–656.
   PubMed Web of Science ®Google Scholar
• Schild L, Kellenberger S. Structure function relationships of ENaC and its role in sodium handling. Adv Exp Med Biol 2001; 502: 305–314.
   PubMedGoogle Scholar
• Eaton DC, Malik B, Saxena NC, et al. Mechanisms of aldosterone’s action on epithelial Na + transport. J Membr Biol. 2001; 184: 313–319.
   PubMedGoogle Scholar
• Rossier C, Pradervand S, Schild L, Hummler E. Epithelial sodium channel and the control of sodium EnaC. Annu Rev Physiol 2002; 64: 877–897.
   PubMed Web of Science ®Google Scholar
• Chang SS, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epthelia sodium channel cause salt wasting with hyperkaliemic acidosis, pseudohyperaldosteronism type I. Nat Genet 1996; 12: 248–253.
   PubMed Web of Science ®Google Scholar
• Farman N, Bocchi B. Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 2000; 57: 1364–1368.
   PubMedGoogle Scholar
• Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corti-costerone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983; 80: 6056–6060.
   PubMed Web of Science ®Google Scholar
• Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988: 242: 583–585.
   PubMed Web of Science ®Google Scholar
• Stewart PM, Wallace AM, Valentino R, et al. Mineralocorticoid activity of licorice: 11ß hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 1: 82–86.
   PubMedGoogle Scholar
• Gomez Sanchez CE, Gomez-Sanchez EP, Yamakita N. Endocrine causes of hypertension Semin Nephrol 1995; 15:106-115
   Google Scholar
• Edwards CRW, Stewart PM, Burt D, et al. Localization of 11?HSD-tissue specificity protector of the mineralocorticoid receptor. Lancet 1988; 2: 986–989.
   PubMed Web of Science ®Google Scholar
• Palermo M, Delitala G, Mantero F, et al. Congenital deficiency of 11?-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary-free cortisol and cortisone. J Endocrinol Invest 2001, 24: 17–23.
   PubMedGoogle Scholar
• Agarwal AK. Cloning and expression of rat cDNA encoding corticosteroid 11?-dehydro-genase. J Biol Chem 1989; 264: 19939–18943.
   Google Scholar
• Albiston AL, Obeyesekere VR, Smith RE, et al. Cloning and tissue distribution of the human 11?-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105: R11–R17.
   Google Scholar
• Conn, JW, Knopf RF, Nesbit RM. Primary aldosteronism: present evaluation of its clinical characteristics and of the results of surgery. In: EE Baulieu and P Robel, eds. Aldosterone. Pp 327–338. Oxford: Blackwell Scientific Publications 1964.
   Google Scholar
• Gross EG, Dexter JD, Roth HG. Hypokalaemic myopathy with myoglobinuria associated with licorice ingestion. N Engl J Med 1966; 274: 602–604.
   PubMed Web of Science ®Google Scholar
• Theophrastus: Inquiry into Plants and Minor Works on Odours and Weather Signs (transl. by Hort A), IX, 13. Harvard University Press, London, 1961.
   Google Scholar
• Plinius: C. Plinii Secundi Naturalis historiae libri XXXVII, XI, 119; XXV, 43. II: Teubneri, Lipsiae, 1875; IV.
   Google Scholar
• Baumann EJ, Kurland S. Changes of the inorganic constituents of blood in suprarenalectomized cats and rabbits. J Biol Chem 1927; 71: 281.
   Google Scholar
• Kendall EC. Adrenal cortex extracts. JAMA 1932; 105: 1486.
   Google Scholar
• Wintersteiner O, Pfiffner JJ. Chemical studies on the adrenal cortex III isolation of two new physiologically inactive compounds. J Biol Chem 1936; 116: 291–295.
   Google Scholar
• Rubin MI, Krick ET. Effect of adrenalectomy on salt metabolism in rat. Proc Soc Exp Biol 1933; 31: 228–33.
   Google Scholar
• Reichestein T, von Euw J. Uber Bestandteile der Nebenniererinde. XX. Isolierung der Substanze Q (Desoxycorticosterone) und R sovie weitere Stoffe. Helv Chim Acta 1938; 21: 1197.
   Google Scholar
• Wintersteiner O, Vars HM, Pfiffner JJ. Chemical investigation of the cortical hormone of the adrenal gland. J Biol Chem 1934; 105: 100–102.
   Google Scholar
• Hartman FA, Spoor HJ, Lewis LA. Sodium factor and the adrenal. Science 1939; 89: 204–208.
   PubMedGoogle Scholar
• Kendall EC The function of the adrenal cortex. Proc Staff Meet Mayo Clin 1940; 15: 297–241.
   Google Scholar
• Grollman A. The comparative activity of desoxycorticosterone and other crystalline derivatives and of purified extracts of the adrenal cortex. J Pharmac Exp Therap 1939; 67: 257–262,
   Google Scholar
• Hartman FA. Functions of the adrenal cortex. Endocrinology 1942; 30: 861–865.
   Google Scholar
• Revers FE. Heedt succus liquiritiae een gegenzde werking of de maagweer? Nedl Tijdschr Geneesk 1946; 90: 135–137.
   PubMedGoogle Scholar
• Revers FE. Licorice juice in the therapy of ventricular and duodenal ulcers. Ned Tijdschr Geneesk 1948; 92: 2968–2971.
   PubMedGoogle Scholar
• Molhuysen JA, Gerbandy J, de Vries LA, et al. A licorice extract with desoxycorticosterone like effect. Lancet 1950; 2: 381–386.
   PubMedGoogle Scholar
• Groen J, Pelser H, Willebrands AF, et al. Extract of licorice for treatment of Addison’s disease. N Engl J Med 1951; 244: 471–475.
   PubMedGoogle Scholar
• Strong JA. Serum potassium deficiency during treatment with PAS and liquorice extract. Br Med J 1951; 4378: 998–1002.
   Google Scholar
• Selye H. Physiology and Pathology of Exposure to Stress. Montreal: Acta Inc Med Publisher, 1950.
   Google Scholar
• Earle DP, Sherry S, Eichna LW, et al. Low potassium syndrome due to defective renal tubular mechanism for handling potassium. Am J Med 1951; 11: 283–301.
   PubMed Web of Science ®Google Scholar
• Amelung D. Conversion of cortisone to compound F. J Clin Endocrinol Metab 1953; 13: 1125–1128.
   PubMedGoogle Scholar
• Peterson RE. Metabolism of adrenal cortical steroids. In: Christy ND, ed. The Human Adrenal Cortex. Pp 87-98. New York: Harper and Row, 1971.
   Google Scholar
• Simpson SA, Tait JF. Physicochemical methods of detection of a previously unidentified adrenal hormone. Mem Soc Endocr 1953; 2: 91–94.
   Google Scholar
• Simpson SA, Tait JF. A quantitative method for the bioassay of the effect of the adrenal cortical steroids on mineral metabolism. Endocrinology 1952; 5: 150–161.
   Google Scholar
• Louis LH, Conn JW. Preparation of glycyrrhizinic acid, the electrolyte-active principle of licorice: its effects upon metabolism and upon pituitary-adrenal function in man. J Lab Clin Med 1956; 47: 20–28.
   PubMedGoogle Scholar
• Gross F. Renin und hypertensin physiologische oder pathologische Wirkstoffe? Klin Wschr 1958; 36: 693–706.
   PubMedGoogle Scholar
• Jenny M, Muller AF, Fabre J, et al. Hypokaliemie calose par ingestion abusive d’ extrait de reglisse et d’eau bicarbonatee. Pseudosyndrome de Conn. Schweiz med Wschr 1961; 91: 869–875.
   PubMedGoogle Scholar
• Drosdowski M, Robel P, Sebaoun J. Syndrome de depletion potassique simulant une maladie de Conn, provoquè par la glycyrrhizin. Presse Med 1961; 69: 294–295.
   Google Scholar
• Salassa RM, Mattox VR, Roseviar JW. Inhibition of the mineralocorticoid activity of licorice by spironolactone. J Clin Endocrinol 1962; 22: 1156–1159.
   Google Scholar
• Sturcz J, Solyom J, Kotra ZS, et al. Role of the renin-angiotensin system on the regulation of aldosterone excretion. Excerpta Med Int Congr Series 1963; 67: 378–380.
   Google Scholar
• Liddle JW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldos-teronism but with negligible aldosterone secretion In: Baulieu EE, Robel P, eds. Aldoster-one. Pp 353-368. Oxford: Blackwell Scientific Publications, 1964.
   Google Scholar
• Conn JW, Rovner DR, Cohen EL. Licorice-induced pseudoaldosteronism. JAMA 205: 80-84,1968.
   Google Scholar
• Feldman D, Funder JW, Edelman IS. Subcellular mechanisms in the action of adrenal steroids. Am J Med 1972; 53: 545–60.
   PubMed Web of Science ®Google Scholar
• Werder EA, Zachmann M, Wollmin J, et al. Unusual steroids excretion in a child with low renin hypertension. Res Steroids 1974; 6: 385–392.
   Google Scholar
• Ulmann A, Menard J, Corvol P. Binding of glycyrrhetinic acid to kidney mineralocorticooid and gluicocorticoid receptors. Endocrinology 1975; 97: 46–50.
   PubMed Web of Science ®Google Scholar
• New MI, Levine L, Biglieri EG, et al. Evidence of an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977, 44: 929–934.
   Google Scholar
• Epstein MT, Espiner EA, Donald RA, Hughes H. Effect of eating liquorice on the renin angiotensin aldosterone axis in the normal subjects. Br Med J 1977; I: 488–490.
   Google Scholar
• Epstein MT, Espiner EA, Donald RA, et al. Licorice raises urinary cortisol in man. J Clin Endocrinol Metab 1978; 47: 397–400.
   PubMed Web of Science ®Google Scholar
• Ulick S, Levine L, Gunczler P, et al. A syndrome of apparent mineralocorticoid excess associated with a defect in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49, 757–764
   PubMed Web of Science ®Google Scholar
• Tamura Y, Nishikawa T, Yamada K, et al. Effects of glycyrrhetinic acid and its derivatives on 4-? and 5 ß reductase in rat liver. Arzneimittelforschung 1979; 29: 47–49.
   Google Scholar
• Armanini D, Karbowiak I, Krozowski Z, et al. The mechanism of mineralocorticoid action of carbenoxolone. Endocrinology 1982; 111: 1683–1686.
   PubMedGoogle Scholar
• Armanini D, Karbowiak J, Funder JW. Affinity of licorice derivatives for mineralocorticoid and glucocorticoid receptors. Clin Endocrinol (Oxford) 1983; 19: 606–609.
   Google Scholar
• Hoefnagels WHL, Kloppenborg WC. Antimineralocorticoid effects of dexamethasone in subjects treated with glycyrrhizic acid. J Hypertension 1983; 1: 313–315.
   Google Scholar
• Armanini D, Zennaro MC, Martella L, et al. Regulation of aldosterone receptors in hypertension. Steroids 1993; 58: 611–613.
   PubMedGoogle Scholar
• Wehling M, Armanini D, Strasser T, et al. Effect of aldosterone on sodium and potassium concentrations in human mononuclear leukocytes. Am J Physiol 1987; 252: E505–508.
   PubMedGoogle Scholar
• Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268–275.
   PubMed Web of Science ®Google Scholar
• Armanini D, Wehling M, Weber PC: Mineralocorticoid effector mechanism of licorice derivatives in human mononuclear leukocytes. J Endocrinol Invest 1989; 12: 303–306.
   PubMedGoogle Scholar
• Armanini D, Scali M, Zennaro MC, et al. The pathogenesis of pseudohyperaldosteronism from carbonexolone. J Endocrinol Invest 1989; 12: 337–314.
   PubMed Web of Science ®Google Scholar
• Dorfman RI, Potts AM, Feil ML. Studies of the bioassay of hormones: the use of radioso-dium for the detection of small quantities of desoxycorticosterone. Endocrinology 1947; 41: 464–469.
   PubMedGoogle Scholar
• Mattox VR, Mason HL, Albert A. Isolation of a sodium retaining substance from beef adrenal extracts. Proc Staff Meet Mayo Clinic 1953; 28, 569–576.
   PubMedGoogle Scholar
• Bartter FC. The role of aldosterone in normal homeostasis and in certain diseases Metabolism 1956; 3: 369–379.
   Google Scholar
• Kliman B, Peterson RE. Isotope derivative assay of aldosterone in biological extracts. Fed Proc 1958; 17: 255–262.
   Google Scholar
• Ulick S, Laragh JH, Lieberman S, et al. The isolation of a urinary metabolite of aldosterone and its use to measure the rate of secretion of aldosterone by the adrenal cortex of man Trans. Ass Am Physns 1958; 71: 225–234.
   PubMedGoogle Scholar
• Genest J, Boucher R, De Champlain J, et al. Studies on the renin angiotensin system in hypertensive patients. CMAJ 1964; 90: 263–271.
   PubMedGoogle Scholar
• Morris DJ, Berek JS, Davis RP. Physiological response to aldosterone in adrenalectomised and intact rats and its sex dependence. Endocrinology 1973; 92: 989–992.
   PubMed Web of Science ®Google Scholar
• Edmonds CJ, Marriot J. The effect of aldosterone and adrenalectomy on the electrical potential difference of rat colon and on the transport of sodium, potassium, chloride and bicarbonate. J Endocrinol 1967; 39: 517–531.
   PubMedGoogle Scholar
• Skrabal F, Aubock J, Edwards CR, et al. Subtraction potential difference: in vivo assay for mineralocorticooid activity. Lancet 1978; i: 298–302.
   Google Scholar
• Mayes D, Furuyama S, Kem DC, et al. A radioimmunoassay for aldosterone. J Clin Endocrinol Metab 1970; 30: 682–688.
   PubMed Web of Science ®Google Scholar
• Stockigt JR, Collins RD, Biglieri EG. Determination of plasma renin concentration by angiotensin I immunoassay. Diagnostic import of precise measurement of subnormal renin in hyperaldosteronism. Circ Res 1971; 28: 175–191.
   PubMedGoogle Scholar
• Lan CN, Matulich DT, Stockigt JR, et al. Role of steroids in various stated of mineralocor-ticoid-excess: analysis by mineralocorticoid receptor assay. In: Giovannelli G, ed. Hypertension in Children and Adolescents. Pp 165-175. New York: Raven Press, 1981.
   Google Scholar
• Armanini D, Lewicka S, Pratesi C, et al. Further studies on the mineralocorticoid action of licorice in humans. J Endocrinol Invest 1996; 19: 624–629.
   PubMed Web of Science ®Google Scholar
• Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119–123.
   PubMed Web of Science ®Google Scholar
• Heilmann P, Buchlein E, Wacker J, et al. Alteration of the activity of the 11?-hydroxysteroid dehydrogenase in pregnancy: relevance for the development of pregnancy-induced hypertension? J Clin Endocrinol Metab 2001; 86: 5222–5226.
   PubMedGoogle Scholar
• Ferrari P, Krowowski Z. Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int 2000; 57: 1374–1381.
   PubMedGoogle Scholar
• Mune T, Roberson FM, Nikkila H et al. Human hypertension caused by mutation in the kidney isoenzyme of 11 ?-hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 394–399.
   PubMed Web of Science ®Google Scholar
• Mach RS Fabvre J, Duckert A, Borth R. Action clinique et metabolique de l’aldosterone (electrocortine). Schweiz Med Wschr 1959; 51: 229–237.
   Google Scholar
• Coghlan JP, Denton DA, Goding JR Wright RD. The control of aldosterone secretion. Postgrad Med J 1960; 36: 76–82.
   PubMedGoogle Scholar
• Collins KJ. The action of exogenous aldosterone on the secretion and composition of drug-induced sweat. Clin Sci 1966; 30: 207–211.
   PubMedGoogle Scholar
• Charron RC, Leme CE, Wilson DR, et al. The effect of adrenal steroids on stool composition, as revealed by in vivo dialysis of feces. Clin Sci 1969; 37: 151–159.
   PubMedGoogle Scholar
• Conn JW, Louis HL, Johnston MW, et al. The electrolyte content of thermal sweat as an index of adrenal cortical function. J Clin Invest 1948; 27: 529–533.
   PubMed Web of Science ®Google Scholar
• Armanini D, Zennaro MC, Martella L, et al. Mineralocorticoid effector mechanism in preeclampsia. J Clin Endocrinol Metab 1992; 74: 946–949.
   PubMed Web of Science ®Google Scholar
• Warnock DG. Genetic forms of human hypertension. Curr Opin Nephrol Hypertens 2001; 10: 493–9.
   PubMedGoogle Scholar
• Hakan R, Toka HR, Luft F. Monogenic forms of human hypertension. Sem Nephrol 2002; 22: 81–88.
   PubMedGoogle Scholar
• Persu A, Barbry P, Bassilana F et al. Genetic analysis of the beta subunit of the epithelial sodium channel in essential hypertension. Hypertension 1998; 32: 129–137.
   PubMed Web of Science ®Google Scholar
• Melander O, Orho M, Fagerudd J, et al. Mutations and variants of the epithelial sodium channel gene in Liddle’s syndrome and primary hypertension. Hypertension 1998; 31: 1118–1124.
   PubMed Web of Science ®Google Scholar
• Latif SA, Conca TJ, Morris DJ. The effect of the licorice derivative glycyrrhetinic acid on hepatic 3? and 3? hydroxysteroid dehydrogenase and 5? and 5? reductase pathways metabolism of aldosterone in male rats. Steroids 1990; 55: 52–60.
   PubMedGoogle Scholar
• Scali M, Pratesi C, Zennaro MC, et al. Pseudohyperaldosteronism from licorice-containing laxatives. J Endocrinol Invest 1990; 13: 847–848.
   PubMedGoogle Scholar
• Mitchell W, Strong JA, Taylor NRW, et al. Effects of liquorice and its derivates on salt and water metabolism. Lancet 1953; i: 663–666.
   Google Scholar
• Blachley JD, Knochel JP. Tobacco chewer’s hypokalemia: licorice revisited. N Engl J Med 1980; 302: 784–785.
   PubMed Web of Science ®Google Scholar
• Ferrari P, Trost BN. A case from practice. Liquorice induced pseudohyperaldosteronism in a previously alcoholic woman caused by the drinking of an alcohol free pastis substitute beverage. Schweiz Rundsch Med Prax 1990; 79: 377–378.
   PubMedGoogle Scholar
• Farese RV Jr, Biglieri EG, Shackleton CH, et al. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325: 1233–1237.
   Google Scholar
• Helmann P, Heide J, Hundertmark S, et al. Administration of acid: significant correlation between serum levels and the cortisol/cortisone ratio in serum and urine. Exp Clin Endocinol Diabetes 1999; 107: 370–378.
   PubMedGoogle Scholar
• Ferrari P, Sansonnens A, Dick B, et al. In vivo 11(3HSD2 activity variability, salt sensitivity and effect of licorice. Hypertension 2001; 38:1330-1336.
   PubMedGoogle Scholar
• Pinder RM, Brogden RN, Stawyer PR, et al. Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease. Drugs 1976; 11: 245–287.
   PubMed Web of Science ®Google Scholar
• Baron JH. Side-effects of carbenoxolone. Acta Gastroenterol Belg 1983; 46: 463–471.
   Google Scholar
• Porter GA. Synergistic effect of carbenoxolone sodium on aldosterone-enhanced sodium transport in toad skin. In: Baron GHO, Sulivan FM, eds. Carbenoxolone Sodium. pp 34-47. London: Butterfield, 1970.
   Google Scholar
• Morris DJ, Sounes JW. The 11(3OHSD inhibitor carbenoxolone enhanced Na retention by aldosterone and 11 desoxycorticosterone. Am J Physiol 1990; 258: F756–759.
   Google Scholar
• Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyr-rhizic acid and carbenoxolone. Am J Physiol 1992; 263: E1125–1130.
   Google Scholar
• Song DJ, Lorenzo B, Reidenberg MM. Inhibition of 11(3hydroxysteroid dehydrogenase by gossypol and bioflavanoids. J Lab Clin Med 1992; 120: 792–797.
   PubMed Web of Science ®Google Scholar
• Lee JS, Lorenzo BJ, Koufis T, et al. Grapefruit juice and its flavanoids inhibit 11(3 hydroxysteroid dehydrogenase. Clin Pharmacol Ther 1996; 59: 62–71.
   PubMed Web of Science ®Google Scholar
• Irony I, Biglieri EG, Perloff D, et al. Pathophysiology of desoxycorticosterone secreting adrenal tumors. Clin Endocrinol Metab 1987; 65: 836–840.
   Google Scholar
• Kondo K, Saruta T, Saito I. Benign desoxycorticosterone producing adrenal tumor. JAMA 1976; 236: 1042–1044.
   PubMedGoogle Scholar
• Doerr HG, Sippel WG, Drop SL Evidence of 11 (3-hydroxylase deficiency in children adrenocortical tumors. The plasma corticosterone/11deoxycorticosterone ratio as a possible marker of malignancy. Cancer 1987; 60: 1625–1629.
   PubMedGoogle Scholar
• Sheppard TH, Clausen SW. Case of adrenogenital syndrome with hypertension-treated with cortisone. Pediatrics 1951; 8: 805–808.
   PubMedGoogle Scholar
• White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (arg448—>his) associated with steroid 11(3hydroxylase deficiency in Jews of Morrocan origin. J Clin Invest 1991; 87:1664-1667.
   Google Scholar
• Lipsett M, Wilson H. Adrenocortical cancer: steroid synthesis and metabolism evaluated by urinary metabolites. J Clin Endocrinol Metab 1962; 22; 906–915.
   PubMedGoogle Scholar
• Mantero F, Opocher G, Armanini D, et al. 11(3 hydroxylase deficiency. J Endocrinol Invest 1995; 18: 545–549.
   PubMedGoogle Scholar
• Mantero F, Busnardo B, Riondel Aveyrat R, et al. Arterial hypertension, hypokalemia alkalosis and male pseudohermaphroditism caused by 17alpha hydroxylase deficiency. Schweiz Med Wochenschr 1971; 101: 38–43.
   PubMedGoogle Scholar
• Biglieri EG. 17cc-hydroxylase deficiency. J Endocrinol Invest 1995; 18: 540–544.
   PubMedGoogle Scholar
• Powell-Jackson JD, Calin A, Freser A. Excess deoxycorticosterone secretion from adrenocortical carcinoma. Br Med J 1974; 2: 32–33.
   PubMedGoogle Scholar
• Biglieri EG, Herron MA, Brust N. 17a hydroxylase deficiency in man. J Clin Invest 1954; 45: 1946–1954.
   Google Scholar
• Mills IH, Wilson RJ, Tait AD, et al. Steroid metabolic studies in a patient with 17a-hydroxylase deficiency syndrome. J Endocrinol 1967: 38: 19–24.
   Google Scholar
• Melby JC, Dahle SL, Grekin R, et al. 18-hydroxydeoxycorticosterone secretion in experimental human hypertension. Prog Horm Res 1972; 28: 287–351.
   PubMedGoogle Scholar
• Irony I, Biglieri EG, Kater CE. The adrenocortical hormones in hypertensive disorders. In: Laragh JH, Brenner BM, Kaplan NM, eds. Endocrine Mechanism in Hypertension. Pp 1-18. New York: Raven Press, 1989.
   Google Scholar
• Vita G, Bartolone S, Santoro M, et al. Hypokalemic myopathy in pseudohyperaldosteronism induced by fluoroprednisolone-containing nasal spray. Clin Neuropathol 1987; 6: 80–85.
   PubMedGoogle Scholar
• Marin F, Gonzales QA, Moya M, et al. Pseudohyperaldosteronism due to application of an anti-hemorroid cream. Nephron 1989; 52: 281–282.
   PubMedGoogle Scholar
• Ambruster H, Vetter W, Reigh G, et al. Severe arterial hypertension caused by chronical abuse of a topical mineralocorticoid. Int J Pharmacol 1975; 12: 170–173.
   Google Scholar
• Mantero F, Armanini D, Opocher G, et al. Mineralocorticoid hypertension due to a nasal spray containing 9a fluoroprednisolone. Am J Med 1981; 71: 352–357.
   PubMed Web of Science ®Google Scholar
• Mijares M. Hypocalemic rhabdomyolysis secondary to pseudohyperaldosteronism due to the use of a lotion containing 9a fluoroprednisolone. Nephron 1986; 43: 232–233.
   PubMedGoogle Scholar
• Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979; 301:68–73.
   PubMed Web of Science ®Google Scholar
• Page B, Zahir A, Grunfield JP. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60–65.
   PubMedGoogle Scholar
• Whithworth JA. Mechanisms of glucocorticoid-induced hypertension in humans. Hypertension 1992; 19: 567–574
   PubMedGoogle Scholar
• Miyamori I. Mechanism of hypertension in Cushing’s syndrome: possible role of 11(3 hydroxysteroid-dehydrogenase. Intern Med 2002; 41: 249–250.
   PubMedGoogle Scholar
• Stewart PM. Cortisol as a mineralocorticoid in human disease. J Ster Biochem Molec Biol 1999; 69: 403–408.
   PubMedGoogle Scholar
• Melander O, Orho-Melander M, Bengtsson K, et al. Association between a variant in the 11(3 hydroxysteroid dehydrogenase type 2 gene and primary hypertension. J Hum Hypertens 2000; 14: 819–823.
   PubMed Web of Science ®Google Scholar
• Mune T, Rogerson FM, Nikkila H et al. Human hypertension caused by mutation in the kidney isoenzyme of 11 ?-hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 394–399.
   PubMed Web of Science ®Google Scholar
• Odermatt A, Dick B, Arnold P. A mutation in the cofactor binding domain of 11?-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension J Clin Endocrinol Metab 2001; 86: 1247–1252.
   Google Scholar
• Palermo M, Cossu M, Shackleton CHL. Cure of apparent mineralocorticoid excess by kidney transplantation. N Engl J Med 1998; 339: 1787–1788.
   PubMedGoogle Scholar
• Sandeep TC, Walker BR. Pathophysiology of modulation of local glucocorticoid levels by 11?-hydroxysteroid dehydrogenase. Trends Endocrinol Metab 2001; 12: 448–453.
   Google Scholar
• Kaplan NM. Hypertension induced by pregnancy, oral contraceptives and postmenopausal replacement therapy. Cardiol Clin 1988; 6: 475–482.
   PubMedGoogle Scholar
• Kem DC. Sex steroids. In: Izzo JL, Black HR, eds. Hypertension. Pp 21-22. Dallas: Primer American Heart Association, 1993.
   Google Scholar
• Saruta T, Ozawa Y, Asano S. The mechansism of estrogen hypertension. Jpn Circ J 1972; 36: 611–616.
   PubMedGoogle Scholar
• Warnock DG. Low renin hypertension in the next millennium. Semin Nephrol 2000; 40: 6–21.
   Google Scholar
• Rossi E, Regolisti G, Perazzoli F, et al. 344C/T polymorphism of CYP11B2 gene in Italian patients with low-renin hypertension. Am J Hypertens 2001; 14: 934–1941.
   PubMedGoogle Scholar
• Fisher ND, Hurwitz S, Ferri C et al. Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. Hypertension 1999; 34: 388–394.
   PubMed Web of Science ®Google Scholar
• Warnock DG. Low-renin and non-modulating essential hypertension. Hypertension 1999; 34: 395–397
   PubMedGoogle Scholar
• Iki K, Miyamori I, Hatakeyama H, et al. The activities of 5?-reductase and 11-? hydroxysteroid dehydrogenase in hypertension. Steroids 1994; 59: 656–660.
   PubMedGoogle Scholar
• Soro A, Ingram MC, Tonolo MG, et al. Evidence of coexisting changes in 11?-hydroxysteroid dehydrogenase and 5?-reductase in patients with untreated essential hypertension. Hypertension 1995; 25: 67–70.
   PubMed Web of Science ®Google Scholar
• Ambrosius WT, Bloem LJ, Zhou L, et al. Genetic variants in the epithelia sodium channel in relation to aldosterone and potassium excretion and of hypertension. Hypertension 1999; 34: 631–637.
   PubMed Web of Science ®Google Scholar
• Su YR, Rutkowski MP, Klanke CA et al. A novel variant of the beta subunit of the amiloride-sensitive sodium channel in African-Americans. J Am Soc Nephrol 1996; 7: 2543–49.
   PubMed Web of Science ®Google Scholar
• Baker EH, Dong YB, Sagnella GA, et al. Association of hypertension with T594M mutation in the beta subunit of epithelial sodium channels in black people resident in London. Lancet 1998; 51:1388-92.
   Google Scholar
• Snyder PM. The epithelial sodium channel: cell surface insertion and retrieval in sodium homeostasis and hypertension. Endocr Rev 2002; 23: 258–275.
   PubMed Web of Science ®Google Scholar
• Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11?-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262–265.
   PubMed Web of Science ®Google Scholar
• Lovati E, Ferrari P, Dick B, et al. Molecular basis of human salt sensitivity: the role of the ?-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 2000; 85: 4921–23.
   Google Scholar
• Manunta P, Cusi D, Barlassina C, et al. Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int. 1998; 53: 1471–8.
   PubMedGoogle Scholar
• Manunta P, Burnier M, D’Amico M, et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 1999; 33: 694–7.
   PubMed Web of Science ®Google Scholar
• Grant FD, Romero JR, Jeunemaitre X, et al. Low-renin hypertension, altered sodium homeostasis, and an alpha-adducin polymorphism. Hypertension 2002: 39:191-96.
   PubMedGoogle Scholar
• Warnock DG. Liddle’s syndrome: genetics and mechanisms of sodium channel defects. Contrib Nephrol 2001; 136: 1–10.
   Google Scholar
• Morris DJ, Semafuko WEB, Latif SA, et al. Detection of glycyrrhetinic like factors in human urine. Hypertension 1992; 20: 356–360.
   PubMed Web of Science ®Google Scholar
• Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle’s syndrome revisited — a disorder of sodium reabsorbtion in the distal tubule. N Engl J Med 1994: 330:178-181.
   PubMedGoogle Scholar
• Lifton RP, Gharavi AG, Geller DS Molecular mechanism of human hypertension. Cell 2001; 104: 546–556.
   Google Scholar